AMEX:AENTime: 4:01pm
Date: 9/2/2010
Last: 0.81
Change: -0.036
High: 0.84
Low: 0.80
CLIA-Certified
Clinical Testing
Laboratory
Adeona (AMEX:AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona’s primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to an inflection point in valuation resulting in a significant development and marketing collaboration.
Trimesta (estriol) is an investigational oral drug for the treatment of relapsing remitting multiple sclerosis. A 150-patient, 16-center, randomized, double-blind, placebo-controlled clinical trial is currently underway. Effirma (flupirtine) is a centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome. Adeona has entered into a potential $17.5 million corporate partnership with Meda AB. As part of the agreement, Meda will assume all future development costs while Adeona is entitled to receive milestone payments and royalties. Zinthionein ZC (zinc cysteine) is an oral, gastro-retentive, sustained-release medical food candidate being developed for the dietary management of Alzheimer’s disease and mild cognitive impairment. A 60-patient randomized double-blind, placebo-controlled clinical study is currently underway. dnaJP1 (hsp peptide) is an investigational oral drug for the treatment of rheumatoid arthritis. It has completed a 160-patient, multi-center, randomized, double-blind, placebo-controlled clinical trial. ZincMonoCysteine (zinc-monocysteine) is an investigational oral drug for the treatment of dry age-related macular degeneration. It has completed an 80-patient, randomized, double-blind, placebo-controlled clinical trial.
| Program | Medical Indications | Stage of Development |
|---|---|---|
| Treatment of relapsing remitting multiple sclerosis in women | 10-patient, 22-month, single-agent, crossover clinical trial completed, and a 150-patient, 16-center, randomized, double-blind, placebo-controlled clinical trial underway | |
| Treatment of fibromyalgia | IND approved and IRB reviewed for 90-patient clinical trial |
|
| Dietary management of Alzheimer’s disease and mild cognitive impairment | 60-patient, randomized, double-blind, placebo-controlled clinical study underway | |
| Treatment of rheumatoid arthritis | 160-patient, multi-center, randomized, double-blind, placebo-controlled clinical trial completed | |
| Treatment of dry age-related macular degeneration | 80-patient, randomized, double-blind, placebo-controlled clinical trial completed |
Adeona Announces Second Quarter 2010 Profitability and Achievements Company Achieves $979,782
Second Quarter Net Income
ANN ARBOR, MI – August 16, 2010 – Adeona Pharmaceuticals, Inc. (AMEX:AEN - News) announced today its second quarter 2010 financial results and recent achievements.
Read More»
